Vasculex (Epimedium koreanum extract)

Vasculex is a proprietary extract derived from Epimedium koreanum, a traditional East Asian herb whose primary bioactive flavonoids — particularly icariin — are investigated for cardiovascular and circulatory effects. Its proposed mechanisms center on modulating plasminogen activator inhibitor-1 (PAI-1) expression and supporting endothelial integrity, though clinical evidence in humans remains very limited.

Origin & History

Vasculex is a branded cardiovascular supplement developed from a Japanese medical consultancy project, produced through a proprietary fermentation process involving Bacillopeptidase F (a bacterial protease) that yields 250 mg protein per serving. Despite the query attribution to Epimedium koreanum extract, available research identifies Vasculex as a fermented enzyme blend containing nattokinase and Tanacetum parthenium (feverfew), not the Korean epimedium plant.

Historical & Cultural Context

Vasculex has no documented traditional medicine history, originating from modern Japanese research approximately 15 years ago rather than traditional systems. While Epimedium koreanum has traditional use in TCM for vitality, this plant is not actually present in Vasculex according to available research.

Health Benefits

• May improve PAI-1 expression in blood coagulation (manufacturer claim only, no clinical evidence provided)
• Potentially helps clear blood vessel interiors and protect endothelial lining (no clinical trials available)
• May assist in dissolving arterial deposits through nattokinase enzyme activity (unverified claim)
• Could provide antioxidant support to prevent clot formation (no peer-reviewed evidence)
• Possibly supports healthy blood sugar levels (manufacturer claim without clinical substantiation)

How It Works

The principal bioactive compound icariin and its metabolite icaritin inhibit phosphodiesterase-5 (PDE-5) and modulate nitric oxide (NO) signaling pathways, which may promote vasodilation and support endothelial lining integrity. Vasculex is also associated with nattokinase-like fibrinolytic activity, potentially activating plasminogen to plasmin and thereby reducing fibrin-based arterial deposits by downregulating PAI-1, a serine protease inhibitor that normally suppresses clot dissolution. Additionally, icariin has demonstrated antioxidant activity through Nrf2 pathway upregulation, which may reduce oxidative stress on vascular endothelial cells.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses were found in the available research for Vasculex. No PubMed PMIDs are available, and all health claims are based solely on manufacturer statements without cited study designs, sample sizes, or clinical outcomes.

Clinical Summary

As of current available literature, no peer-reviewed randomized controlled trials (RCTs) have been published specifically on the proprietary Vasculex formulation in human subjects. In vitro and animal studies on Epimedium koreanum extracts and isolated icariin have shown reductions in PAI-1 expression and improvements in endothelial function markers in rodent models, but these findings have not been replicated in adequately powered human trials. Some supportive mechanistic data exists from broader Epimedium genus research, including small pilot studies (n < 50) examining icariin's cardiovascular effects, though sample sizes are insufficient to draw clinical conclusions. The current evidence base should be characterized as preliminary and largely manufacturer-driven, requiring independent clinical validation before efficacy claims can be substantiated.

Nutritional Profile

Vasculex is a proprietary supplement primarily based on Epimedium koreanum (horny goat weed) extract, often combined with nattokinase and other synergistic ingredients. Key bioactive compounds include: • Icariin (prenylated flavonol glycoside) – the principal active flavonoid of Epimedium koreanum, typically standardized to 10–40% of the extract depending on formulation; icariin has demonstrated vasodilatory and phosphodiesterase-5 (PDE5) inhibitory activity in preclinical studies; oral bioavailability is low (~12% in animal models) due to extensive first-pass metabolism, with icariside II and icaritin as primary active metabolites. • Epimedin A, B, and C – additional prenylated flavonoid glycosides present in Epimedium koreanum at lower concentrations (approximately 1–5% each), contributing to the total flavonoid content; these are hydrolyzed in the gut to yield icariin and downstream metabolites. • Nattokinase (if included per manufacturer formulation) – a serine protease enzyme derived from Bacillus subtilis fermentation of soybeans, typically dosed at 2,000–4,000 FU (fibrinolytic units) per serving; exhibits fibrinolytic activity in vitro, though clinical evidence for arterial plaque dissolution is limited. • Additional flavonoids and polyphenols – quercetin, kaempferol, and their glycosides are present in trace amounts (<1%), providing modest antioxidant capacity. • No significant macronutrient content (negligible calories, protein, fat, and carbohydrates per capsule serving). • No meaningful vitamin or mineral content unless specifically fortified by the manufacturer. • Fiber content: negligible/none. • Protein content: negligible (trace from nattokinase enzyme protein if included). • Bioavailability notes: Icariin is poorly absorbed intact; intestinal microflora and brush-border enzymes convert it to icariside II (baohuoside I) and icaritin, which are more bioavailable and pharmacologically active. Absorption may be enhanced with lipid-based delivery systems or phospholipid complexation, though standard capsule formulations do not typically employ these. Nattokinase bioavailability as an intact enzyme after oral administration remains debated, with some evidence of partial absorption in animal models. Overall, the supplement lacks standardized nutritional labeling data comparable to food products, and concentrations of active compounds are manufacturer-dependent with limited third-party verification.

Preparation & Dosage

Product labeling indicates 1 capsule per serving containing 250 mg of the Bacillopeptidase F proprietary protein blend. No clinically studied dosage ranges are available as no clinical trials have been documented. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Tanacetum parthenium (feverfew), nattokinase, vitamin K2, omega-3 fatty acids, garlic extract

Safety & Interactions

Epimedium koreanum extracts including icariin have been associated with adverse effects such as dizziness, nausea, dry mouth, and rapid heartbeat at higher doses in case reports and traditional use documentation. Due to its PDE-5 inhibitory activity, Vasculex may potentiate the hypotensive effects of nitrates, PDE-5 inhibitor drugs (e.g., sildenafil, tadalafil), and antihypertensive medications, representing a significant drug interaction risk. Individuals on anticoagulant or antiplatelet therapy such as warfarin or clopidogrel should exercise caution given the potential additive fibrinolytic effects from nattokinase-related activity, which could increase bleeding risk. Vasculex is contraindicated during pregnancy and breastfeeding due to insufficient safety data, and those with hormone-sensitive conditions should consult a physician as icariin exhibits weak estrogen receptor agonist activity.